Solé Carla, Goicoechea Ibai, Goñi Alai, Schramm Maike, Armesto María, Arestin María, Manterola Lorea, Tellaetxe Maitena, Alberdi Aitor, Nogueira Leonor, Roumiguie Mathieu, López Jose Ignacio, Sanz Jaka Juan Pablo, Urruticoechea Ander, Vergara Itziar, Loizaga-Iriarte Ana, Unda Miguel, Carracedo Arkaitz, Malavaud Bernard, Lawrie Charles H
Molecular Oncology group, Biodonostia Research Institute, 20014 San Sebastián, Spain.
Multiple Myeloma Group, Centro de Investigación Médica Aplicada (CIMA), Pamplona, 31008 Navarra, Spain.
Cancers (Basel). 2020 Feb 22;12(2):513. doi: 10.3390/cancers12020513.
Prostate cancer (PCa) is the second most common cancer of men and is typically slow-growing and asymptomatic. The use of blood PSA as a screening method has greatly improved PCa diagnosis, but high levels of false positives has raised much interest in alternative biomarkers. We used next-generation sequencing (NGS) to elucidate the urinary transcriptome of whole urine collected from high-stage and low-stage PCa patients as well as from patients with the confounding diagnosis of benign hyperplasia (BPH). We identified and validated five differentially expressed protein-coding genes (, , , and ) in an independent validation cohort of small-volume (1 mL) centrifuged urine ( = 94) and non-centrifuged urine ( = 84) by droplet digital (dd)PCR. These biomarkers were able to discriminate between BPH and PCa patients and healthy controls using either centrifuged or non-centrifuged whole urine samples, suggesting that the urinary transcriptome is a valuable source of non-invasive biomarkers for PCa that warrants further investigation.
前列腺癌（PCa）是男性中第二常见的癌症，通常生长缓慢且无症状。使用血液前列腺特异抗原（PSA）作为筛查方法极大地改善了前列腺癌的诊断，但高假阳性率引发了人们对替代生物标志物的浓厚兴趣。我们使用下一代测序（NGS）来阐明从高分期和低分期前列腺癌患者以及患有混淆诊断的良性前列腺增生（BPH）患者收集的全尿的尿液转录组。我们通过液滴数字（dd）PCR在一个独立的小体积（1 mL）离心尿（n = 94）和非离心尿（n = 84）验证队列中鉴定并验证了五个差异表达的蛋白质编码基因（、、、和）。这些生物标志物能够使用离心或非离心的全尿样本区分BPH患者、前列腺癌患者和健康对照，这表明尿液转录组是前列腺癌非侵入性生物标志物的宝贵来源，值得进一步研究。
